Abstract:RRP is caused by HPV infection of the aerodigestive tract that significantly impacts quality‐of‐life including the ability to communicate and breathe. This study aims to determine whether rationale exists for combination therapeutic approaches using VEGF inhibitors and/or immune checkpoint blockade. Our analysis shows that RRP tissue shows elevated levels of multiple immune check point targets and VEGFR3, with varied patterns unique to each papilloma patient. Some of these immune checkpoint markers already have novel immunotherapies available or in development, providing molecular rationale to offer these systemic treatments to selected patients affected by RRP alongside VEGF inhibitors. Objectives Recurrent respiratory papillomatosis (RRP) is caused by human papilloma virus (HPV) infection of the aerodigestive tract that significantly impacts quality‐of‐life including the ability to communicate and breathe. Treatment was traditionally limited to serial ablative procedures in the O.R. with possible local adjuvant therapy, but new systemic therapies, such as Vascular endothelial growth factor (VEGF) inhibitors, are showing significant promise. This study aims to determine whether rationale exists for combination therapeutic approaches using VEGF inhibitors and/or immune checkpoint blockade. Methods Using fresh specimens from the O.R., we performed flow cytometry on papilloma, normal adjacent tissue, and blood. Papilloma and surrounding tissue were examined for expression of PD‐L1, PD‐L2, Galectin‐9, VEGFR2, and VEGFR3. CD8+ and CD4+ T cells were assayed for expression of PD‐1, TIGIT, LAG3, and TIM3. Results Our data shows that papilloma tissue exhibits significantly higher levels of PD‐L1 and PD‐L2 compared to adjacent tissue. Elevated levels of the VEGF receptor VEGFR3 were also observed in papilloma tissue. When examining T cells within the papilloma, elevated PD‐1 and TIGIT expression was observed on CD8+ T cells, while levels of PD‐1, TIGIT, and TIM3 were elevated on CD4+ T cells compared to PBMCs. Heterogenous marker expression was observed between individuals. Conclusions Our analysis shows that RRP tissue shows elevated levels of multiple immune check point targets and VEGFR3, with varied patterns unique to each papilloma patient. Some of these immune checkpoint markers already have novel immunotherapies available or in development, providing molecular rationale to offer these systemic treatments to selected patients affected by RRP alongside VEGF inhibitors. Laryngoscope, 2024

HPV Vaccines for Treatment and Prevention of Recurrent Respiratory Papillomatosis

Human papilloma virus (HPV) vaccination is associated with reduced number of surgical treatments, an observational study on recurrent respiratory papillomatosis in Northern Sweden

Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes

Trends in the incidence and prevalence of juvenile-onset recurrent respiratory papillomatosis following implementation of national HPV vaccination initiatives: a systematic review

Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis

VEGF as a Key Actor in Recurrent Respiratory Papillomatosis: A Narrative Review

[Update on HPV-associated head and neck cancers-highlights of the 2024 ASCO Annual Meeting]

Effectiveness of combined approach to recurrent respiratory papillomatosis (RRP)

Experimental Research on the Therapeutic Effect of MMR Vaccine to Juvenile-Onset Recurrent Respiratory Papillomatosis.

Adjuvant Human Papillomavirus Vaccination in Recurrent Respiratory Papilloma Patients Older than 45.

Recurrent respiratory papillomatosis: Immunological mechanisms involved in recurrence

Pulmonary Spread Of Juvenile Laryngeal Papillomatosis: A Case Report

Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution's Experience

Successful Bevacizumab Therapy in a 25-Year-Old Patient with Recurrent Respiratory Papillomatosis

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis

Forecasting Disease Burden with a Dynamic Transmission Model of Human Papillomavirus and Recurrent Respiratory Papillomatosis in the United States

Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review

Current Practice, Safety and Efficacy of Interventions for Recurrent Respiratory Papillomatosis: Evidence From a UK Registry

Human papillomavirus vaccines and adolescents

Update on Pathologic Conditions, Imaging Findings, Prevention, and Management of Human Papillomavirus-related Neoplasms

Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer